A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) Therapy

NCT03796858 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

285

Enrollment

INDUSTRY

Sponsor class

Conditions

Arthritis, Psoriatic

Interventions

DRUG: Guselkumab 100 mg
DRUG: Placebo

Sponsor

Janssen Pharmaceutica N.V., Belgium